{
    "organizations": [],
    "uuid": "19fdf422875ca33818f7bf1a5da6849a5566bc15",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-onxeo-provides-update-on-litigatio/brief-onxeo-provides-update-on-litigation-with-spebio-spepharm-idUSFWN1PI191",
    "ord_in_thread": 0,
    "title": "BRIEF-Onxeo Provides Update on Litigation with SpeBio/SpePharm",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - Onxeo SA:\n* ONXEO SA - SUBMITTED CONCLUSIONS TO PARIS COURT OF APPEAL CONCERNING MERITS OF LITIGATION AGAINST SPEPHARM/SPEBIO B.V COMPANIES\n* ONXEO SA - COURTâ€˜S DECISION IS EXPECTED AS EARLY AS END OF Q4 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-24T04:37:00.000+02:00",
    "crawled": "2018-01-24T15:52:07.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "onxeo",
        "sa",
        "onxeo",
        "sa",
        "submitted",
        "conclusion",
        "paris",
        "court",
        "appeal",
        "concerning",
        "merit",
        "litigation",
        "company",
        "onxeo",
        "sa",
        "court",
        "decision",
        "expected",
        "early",
        "end",
        "q4",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}